Biblio
2023
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang M-C, Cairoli R, Hou H-A, Kwong Y-L, Arnan M, Meers S, et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2023.